Overview

• Pfizer confirmed an agreement to lower the cost of some prescription drugs in the United States, but neither side disclosed the scope or size of the cuts.
• The White House said the deal includes selling certain Pfizer products to Medicaid at reduced rates.
• The announcement arrived as the administration’s deadline for drugmakers to submit price‑reduction proposals tied to a May executive order expired.
• The White House is promoting a planned direct‑to‑consumer website called TrumpRX for purchasing medicines at reduced prices, with launch specifics still unknown.
• Officials continue to wield tariff threats, including a reported 100% levy on branded drugs not made in the U.S., even as prior court blocks of similar policies and industry direct‑sales responses signal legal and market uncertainty.